Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Mutated Non-small Cell Lung Cancer Patients”

441 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 441 results

Testing effectiveness (Phase 2)Looking for participantsNCT06563999
What this trial is testing

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Who this might be right for
Lung Cancer Stage IIIMutation
Sun Yat-sen University 120
Not applicableEnded earlyNCT02483416
What this trial is testing

Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 30
Early research (Phase 1)Study completedNCT02729298
What this trial is testing

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsEGFR Positive Non-small Cell Lung CancerColorectal Carcinoma+2 more
Sumitomo Pharma America, Inc. 177
Testing effectiveness (Phase 2)Active Not RecruitingNCT06194448
What this trial is testing

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

Who this might be right for
Lung Cancer
AstraZeneca 76
Large-scale testing (Phase 3)Ended earlyNCT04816214
What this trial is testing

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 6
Not applicableUnknownNCT05136014
What this trial is testing

Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model

Who this might be right for
Lung CancerLung AdenocarcinomaEGFR Activating Mutation+2 more
Central Hospital, Nancy, France 200
Early research (Phase 1)Study completedNCT04959981
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Who this might be right for
Advanced Non-squamous Non-small-cell Lung Cancer
Erasca, Inc. 24
Testing effectiveness (Phase 2)Looking for participantsNCT05284539
What this trial is testing

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Hunan Province Tumor Hospital 760
Large-scale testing (Phase 3)Ended earlyNCT02588261
What this trial is testing

ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Astellas Pharma Global Development, Inc. 530
Not applicableStudy completedNCT00997230
What this trial is testing

Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m

Who this might be right for
Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca 4,243
Large-scale testing (Phase 3)Active Not RecruitingNCT04351555
What this trial is testing

Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 358
Testing effectiveness (Phase 2)Looking for participantsNCT06071013
What this trial is testing

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Who this might be right for
Non-small Cell Lung CancerEGFR Gene MutationEGFR-TKI Resistant Mutation
China Medical University Hospital 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06018688
What this trial is testing

Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.

Who this might be right for
Non Small Cell Lung CancerEGFR Gene Mutation
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 44
Testing effectiveness (Phase 2)UnknownNCT01391260
What this trial is testing

Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
ZhuGuangYing 30
Large-scale testing (Phase 3)UnknownNCT02824458
What this trial is testing

Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

Who this might be right for
EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors
Sun Yat-sen University 246
Large-scale testing (Phase 3)UnknownNCT02859077
What this trial is testing

EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Who this might be right for
Non-Small-Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 100
Not applicableUnknownNCT01382992
What this trial is testing

A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Peking Union Medical College Hospital 150
Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Testing effectiveness (Phase 2)UnknownNCT04895930
What this trial is testing

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
Shanghai Chest Hospital 40
Testing effectiveness (Phase 2)Study completedNCT01250119
What this trial is testing

Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 688
Load More Results